Zimbabwe has turned down a substantial American health deal worth $367m (272 million pounds) spanning five years over the United States' insistence on confidential biological samples.
The decision came to light following a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative has since clarified that the United States was seeking health data for scientific study and profit while was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued talks to secure a deal agreeable to all parties so the nation's vital HIV programme can be sustained.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a court halted a related deal with the US after legal challenges were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to enhance openness and responsibility.
As per statements, Sixteen nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the end products would be available to our citizens if a future disease outbreak emerge."
National Interest and International Frameworks
He also said that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining systems already set up via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This framework is intended to ensure that when a country provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration might be arranged in a way that honours the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks must proceed considering much of the country's HIV programmes were funded by external financing.
"In cases where specific concerns arise, such as those involving information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," it said.
The situation emphasises the complex challenges between receiving vital foreign assistance and safeguarding local interests in an ever more data-driven world.